Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 42

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

1048

HTML

7945

Tables (1-2)

338

Sum=9331

Publishing Process of This Article

Item

Count

Browse

1400

Download

1316

Sum=2716

Nov 14, 2013 (publication date) through Apr 18, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Nov 14, 2013; 19(42): 7327-7340
Published online Nov 14, 2013. doi: 10.3748/wjg.v19.i42.7327

Table 2 Drug induced hepatobiliary manifestations in inflammatory bowel disease

Manifestation	Drug
Drug induced hepatitis	Azathioprine
	6-mercaptopurine
	Methotrexate
	Cyclosporine
	Infliximab
Reactivation of hepatitis B	Anti-TNF therapy
	Corticosteroids
Drug induced pancreatitis	Azathioprine
	6-mercaptopurine
	Methotrexate
Hepatosplenic T-cell lymphoma	Combination of anti-TNF and immunosuppressive therapy

TNF: Tumor necrosis factor.

Citation: Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver. World J Gastroenterol 2013; 19(42): 7327-7340
URL: https://www.wjgnet.com/1007-9327/full/v19/i42/7327.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i42.7327